Page last updated: 2024-11-05

isopropyl myristate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isopropyl myristate is an ester formed by the reaction of myristic acid and isopropyl alcohol. It is a clear, colorless, odorless liquid that is insoluble in water but soluble in most organic solvents. Isopropyl myristate is commonly used as a skin-conditioning agent, emollient, and solvent in cosmetics and pharmaceuticals. It is also used as a lubricant, plasticizer, and antifoaming agent in various industrial applications. The ester is often used in skin care products due to its ability to easily penetrate the skin and improve the absorption of other ingredients. Research suggests that isopropyl myristate may have some anti-inflammatory and antioxidant properties. It is studied for its potential to enhance the delivery of drugs and other therapeutic agents to the skin.'

isopropyl myristate: used for microemulsions; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8042
CHEMBL ID207602
CHEBI ID90027
SCHEMBL ID2442
MeSH IDM0051850

Synonyms (125)

Synonym
LS-14615
fema no. 3556
epa pesticide chemical code 000207
1-methylethyl tetradecanoate
nsc 406280
isopropyl myristate [usan]
einecs 203-751-4
brn 1781127
hsdb 626
caswell no. 511e
deltylextra
110-27-0
tetradecanoic acid, 1-methylethyl ester
isopropyl myristate
tetradecanoic acid,isopropyl ester (myristate,isopropyl ester)
inchi=1/c17h34o2/c1-4-5-6-7-8-9-10-11-12-13-14-15-17(18)19-16(2)3/h16h,4-15h2,1-3h
kessco ipm
emerest 2314
estergel
isomyst
plymoutm ipm
tegester
wln: 13voy1&1
tetradecanoic acid, isopropyl
promyr
kessco isopropyl myristate
starfol ipm
myristic acid, isopropyl ester
emcol-im
nsc406280
nsc-406280
kesscomir
isopropyl tetradecanoate
stepan d-50
ja-fa ipm
deltyl extra
crodamol i.p.m.
crodamol ipm
wickenol 101
1-tridecanecarboxylic acid, isopropyl ester
unimate ipm
tetradecanoic acid, isopropyl ester
bisomel
sinnoester mip
isopropyl myristate, >=98%
isopropyl myristate (nf)
D02296
estergel (tn)
isopropyl myristate, 98%
NCGC00164071-01
isopropyl myristate, >=90% (gc)
propan-2-yl tetradecanoate
myristic acid isopropyl ester
CHEMBL207602
chebi:90027 ,
M0481
NCGC00164071-02
tetradecanoic acid 1-methylethyl ester
isopropyl myristate [usan:nf]
unii-0re8k4lnjs
ec 203-751-4
0re8k4lnjs ,
LMFA07010677
we(2:0(1me)/14:0)
cas-110-27-0
NCGC00256937-01
dtxsid0026838 ,
dtxcid306838
tox21_303171
tox21_202065
NCGC00259614-01
tox21_112080
FT-0629053
isopropyl myristate [who-dd]
isopropyl myristate [ep monograph]
isopropyl myristate [hsdb]
myristic acid, isopropyl alcohol ester
isopropyl myristate [usp-rs]
isopropyl myristate [ii]
isopropyl myristate [fhfi]
isopropyl myristate [vandf]
isopropyl tetradecanoic acid
tetradeconoic acid, 1-methylethyl ester
isopropyl myristate [inci]
isopropyl myristate [mi]
isopropyl myristate [mart.]
AKOS015902296
S2428
SCHEMBL2442
NCGC00164071-03
tox21_112080_1
Q-201418
lexol ipm
tegosoft m
tetradecanoic acid methyethyl ester
iso-propyl n-tetradecanoate
radia 7190
methylethyl tetradecanoate
liponate ipm
mfcd00008982
SR-01000944751-1
sr-01000944751
isopropyl myristate, united states pharmacopeia (usp) reference standard
isopropyl myristate, pharmaceutical secondary standard; certified reference material
isopropyl myristate, vetec(tm) reagent grade, 98%
isopropyl myristate; 1-methylethyl tetradecanoate
myristic acid-isopropyl ester
crodamol 1pm
fema 3556
1405-98-7
Q416222
DB13966
tetradecanoic acid isopropyl ester
isopropyl-myristate
isopropyltetradecanoate
CS-0085813
HY-124190
EN300-25299830
F71211
deltyextra
isopropyl myristate (usp-rs)
usepa/opp pesticide code: 000207
isopropyl myristate (ii)
isopropyl myristate (mart.)
isopropyl myristate (ep monograph)

Research Excerpts

Overview

Isopropyl myristate (IPM) is a widely used penetration enhancer in pharmaceutical formulations. Its mechanism of action on a molecular scale is still not completely understood.

ExcerptReferenceRelevance
"Isopropyl myristate (IPM) is a widely used penetration enhancer in pharmaceutical formulations, however, its mechanism of action on a molecular scale is still not completely understood. "( The effect of non-deuterated and deuterated isopropyl myristate on the thermodynamical and structural behavior of a 2D Stratum Corneum model with Ceramide [AP].
Brezesinski, G; Dobner, B; Lange, S; Oliveira, JS, 2017
)
2.16

Toxicity

ExcerptReferenceRelevance
" IPM was also well tolerated, with minimal adverse events."( North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz).
Goodman, JJ; Kaul, N; Palma, KG; Silagy, SS; Toole, J,
)
0.37
"Data suggest that IPM is a safe and effective therapy for the treatment of head lice in children and adults."( North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz).
Goodman, JJ; Kaul, N; Palma, KG; Silagy, SS; Toole, J,
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
"This study describes the pharmacokinetic behaviours of taxol after intravenous administration of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate (namely, Taxol-IPM-PLGA-MS) and taxol saline solution to mice."( Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice.
Adachi, I; Horikoshi, I; Sato, H; Wang, YM, 1996
)
0.71

Compound-Compound Interactions

ExcerptReferenceRelevance
" Combined with penetration enhancers, the cumulative amounts were further increased in presence of 5% IPM, which exhibited a flux of 840."( The effect of ion-pair formation combined with penetration enhancers on the skin permeation of loxoprofen.
Fang, L; Hui, M; Quan, P; Yang, Y, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Hydrocortisone was slowly absorbed and did not reach a steady-state absorption rate during the experimental period."( Absorption and metabolism of hydrocortisone 21-butyrate, 21-hemisuccinate and hydrocortisone by skin of the rabbit ear during single-pass perfusion.
Bast, GE; Kampffmeyer, HG, 1994
)
0.29
" These results show that use of IPM can significantly improve the bioavailability of naproxen in topical preparations."( Effectiveness and mode of action of isopropyl myristate as a permeation enhancer for naproxen through shed snake skin.
Jun, HW; Suh, H, 1996
)
0.57
" The bioavailability of naproxen in the topical gel was approximately 2% of the applied dose in dogs."( Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats.
Dzimianski, MT; Jun, HW; Lu, GW; Suh, H, 1997
)
0.3
" The aim of this study was to relate some physicochemical properties (characterised by polarisation and transmission electron microscopy, thermal analysis and rheology) of the three formulations based on cetearyl glucoside and cetearyl alcohol, to the results of in vitro and in vivo bioavailability of hydrocortisone (HC)."( An alkylpolyglucoside surfactant as a prospective pharmaceutical excipient for topical formulations: the influence of oil polarity on the colloidal structure and hydrocortisone in vitro/in vivo permeation.
Müller-Goymann, CC; Savić, M; Savić, S; Tamburić, S; Vesić, S; Vuleta, G, 2007
)
0.34
" In summary, tape-stripping experiments, with careful interpretation, can reveal details of a drug's bioavailability in the skin following topical application and may be used to probe the mechanism(s) by which certain excipients influence local drug delivery."( Effect of propylene glycol on ibuprofen absorption into human skin in vivo.
Guy, RH; Hadgraft, J; Herkenne, C; Kalia, YN; Naik, A, 2008
)
0.35
" However, the further studies of the skin's stimulation and bioavailability are needed."( [Study on alpha-asarone reservoir-type patch].
Chen, HL; Gao, JQ; Hu, Y; Liang, WQ; Wu, Z, 2007
)
0.34
" Microemulsion systems prepared by AOT/Tween85/isopropyl myristate (IPM)/water possessing a potentially improved skin bioavailability of CysA were designed."( Bicontinuous cyclosporin a loaded water-AOT/Tween 85-isopropylmyristate microemulsion: structural characterization and dermal pharmacokinetics in vivo.
Dong, Y; Lang, Y; Li, S; Liu, H; Wang, Y; Yao, H, 2009
)
0.61
"49 mg/L, and the absolute bioavailability was 27."( Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.
Chen, Y; Fang, L; Li, C; Liu, C; Liu, J; Mu, L; Sun, L; Wang, Z; Xi, H, 2012
)
0.38
" Hence, the drug suffers from brief residence in the highly moving intestine during diarrhoea which leads to poor bioavailability and frequent dosing."( Design of innovated lipid-based floating beads loaded with an antispasmodic drug: in-vitro and in-vivo evaluation.
Adel, S; ElKasabgy, NA, 2014
)
0.4
" However, the oral bioavailability of these methoxyflavones has been shown to be low."( Transdermal permeation of Kaempferia parviflora methoxyflavones from isopropyl myristate-based vehicles.
Jaipakdee, N; Limpongsa, E; Sripanidkulchai, B; Tuntiyasawasdikul, S, 2014
)
0.64
" The aim of this project was to improve the solubility and eventually the dermal permeability and bioavailability by developing a microemulsion based gel for PAB (PAB ME-gel)."( Microemulsion based gel for topical dermal delivery of pseudolaric acid B: In vitro and in vivo evaluation.
Pan, J; Pan, W; Qin, M; Wan, T; Wu, C; Wu, Z; Xu, T; Xu, Y; Zhang, G, 2015
)
0.42
"The developed MEs are a viable alternative to conventional eye drops, because of its ability to enhance bioavailability through its longer precorneal residence time and its ability to sustain the release of the drug."( Phase-transition W/O Microemulsions for Ocular Delivery: Evaluation of Antibacterial Activity in the Treatment of Bacterial Keratitis.
Bharti, SK; Kesavan, K, 2017
)
0.46
" It has low oral bioavailability and short halflife."( Optimization of Microemulgel for Tizanidine Hydrochloride.
Brahmane, S; Chabukswar, A; Jagdale, S, 2020
)
0.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"In recent years, the hydrophobic active substances have led researchers to develop new formulations to enhance bioavailability and dissolution rate; brinzolamide, a lipophilic drug belongs to carbonic anhydrase inhibitors, which cause reduction of intraocular pressure in patients suffering from glaucoma."( Ocular microemulsion of brinzolamide: Formulation, physicochemical characterization, and in vitro irritation studies based on EpiOcular™ eye irritation assay.
Aydın, A; Çağlar, EŞ; Charehsaz, M; Siafaka, PI; Sipahi, H; Üstündağ Okur, N, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
"Eye drops are the most used dosage form by the ocular route, in spite of their low bioavailability."( New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
da Silva-Cunha, A; Fialho, SL, 2004
)
0.32
"A transdermal dosage form of trazodone hydrochloride (TZN) may be useful in the treatment of moderate to severe depression in schizophrenic patients by providing prolonged duration of action."( Effect of penetration enhancers on skin permeation of trazodone hydrochloride from matrix type transdermal formulation through mouse and human cadaver epidermis.
Bhattacharya, A; Das, MK; Ghosal, SK,
)
0.13
" Permeation issues for topical delivery systems of such effects are occasionally problematic, and in view of the fact that microemulsions are potential carriers for transdermal delivery system, the objective of this study was to design an optimal microemulsion formulation by in vitro permeation study for hesperetin topical dosage form and determine its topical photoprotective effect and skin irritation by in vivo study."( In vitro permeation and in vivo whitening effect of topical hesperetin microemulsion delivery system.
Huang, CT; Huang, YB; Lee, KF; Tsai, YH; Wu, PC, 2010
)
0.36
"Emulgel dosage form based on Pemulen polymeric emulsifier and JB is a promising vehicle for topical delivery of CZ and further in vivo animal studies are recommended."( Optimized formulation for topical administration of clotrimazole using Pemulen polymeric emulsifier.
Hady, SA; Hammad, M; Mortada, N; Shahin, M, 2011
)
0.37
"15 μg · cm(-2)) and could become a favorable new dosage form for DHPS."( The preparation of 3,5-dihydroxy-4-isopropylstilbene nanoemulsion and in vitro release.
Gao, J; Han, Y; Zhang, R; Zhang, Y; Zheng, H, 2011
)
0.37
"As part of our efforts to further modify the physicochemical properties of this market drug, with the ultimate goal to formulate a better dosage form for GRN, this work was carried out to improve its permeability in vitro."( In vitro percutaneous absorption enhancement of granisetron by chemical penetration enhancers.
Cun, D; Fang, L; Li, L; Li, W; Ma, X; Sun, L; Xi, H; Zhao, N, 2013
)
0.39
" Reform the dosage forms of andrographolide to improve its aqueous solubility and oral bioavailability."( Preparation and evaluation of andrographolide-loaded microemulsion.
Dong, X; Du, H; Feng, Q; Han, L; Li, H; Li, X; Niu, X; Yang, X; Ye, M; Zhu, Q, 2012
)
0.38
"Drug loaded hydrofluoroalkane (HFA) sprays can generate effective pharmaceutical formulations, but a deeper understanding of the manner in which these dynamic systems drive the process of in situ semi-solid dosage form assembly is required."( Topical corticosteroid delivery into human skin using hydrofluoroalkane metered dose aerosol sprays.
Benaouda, F; Brown, MB; Jones, SA; Khengar, R; Reid, ML, 2013
)
0.39
"Gelucire® 43/01 /isopropylmyristate-based calcium alginate floating beads coated with ethylcellulose using either PEG 400 or TEC as plasticizers proved to be a successful dosage form in extending DRT release."( Design of innovated lipid-based floating beads loaded with an antispasmodic drug: in-vitro and in-vivo evaluation.
Adel, S; ElKasabgy, NA, 2014
)
0.4
" In addition, the mock patches were formulated with typical ester ingredients for transdermal dosage forms."( [Pharmaceutical Properties of Anti-inflammatory Analgesic Patches Using Acrylic Polymer].
Fukami, T; Gato, K; Kato, S; Koide, T; Shikaku, R; Yoshimura-Fujii, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (16 Items)

ItemProcessFrequency
en:open-beauty-factscore-ingredient13
Open Beauty Factscore-ingredient7
Chapsticks and lip balmscore-ingredient3
Non food productscore-ingredient3
Productos no alimenticioscore-ingredient3
Cosmetic lotioncore-ingredient1
Non alimentairecore-ingredient1
fr:Crème hydratantecore-ingredient1
de:Deocore-ingredient1
Kosmetisches Mittelcore-ingredient1
hair maskcore-ingredient1
תכשירי-שיערcore-ingredient1
Cosmeticicore-ingredient1
fr:Huile pour cheveuxcore-ingredient1
Exfoliantes corporalescore-ingredient1
Soincore-ingredient1

Drug Classes (1)

ClassDescription
fatty acid esterA carboxylic ester in which the carboxylic acid component can be any fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency0.13800.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency19.35720.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency0.02820.000221.22318,912.5098AID588515
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.60320.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.09630.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.51310.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency42.38290.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.28180.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency48.55770.000323.4451159.6830AID743065; AID743067
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.56230.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID264977Antibacterial activity against Micrococcus luteus2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Design, synthesis, antibacterial, and QSAR studies of myristic acid derivatives.
AID264976Antibacterial activity against Staphylococcus aureus2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Design, synthesis, antibacterial, and QSAR studies of myristic acid derivatives.
AID264978Antibacterial activity against Escherichia coli2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Design, synthesis, antibacterial, and QSAR studies of myristic acid derivatives.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (270)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (7.78)18.7374
1990's35 (12.96)18.2507
2000's92 (34.07)29.6817
2010's103 (38.15)24.3611
2020's19 (7.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 80.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index80.60 (24.57)
Research Supply Index5.69 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index142.89 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (80.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (3.15%)5.53%
Reviews2 (0.70%)6.00%
Case Studies4 (1.40%)4.05%
Observational1 (0.35%)0.25%
Other270 (94.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]